학술논문

발행년
-
(예 : 2010-2015)
'학술논문' 에서 검색결과 64건 | 목록 1~10
Academic Journal
Wu HH; Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, CT, USA. Electronic address: helen.wu@boehringer-ingelheim.com.; Crames M; Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, CT, USA.; Wei Y; Amgen Inc., Drug Product Technologies, Thousand Oaks, CA, USA.; Liu D; Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, CT, USA.; Gueneva-Boucheva K; Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, CT, USA.; Son I; Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, CT, USA.; Frego L; Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, CT, USA.; Han F; Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, CT, USA.; Kroe-Barrett R; Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, CT, USA.; Nixon A; Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, CT, USA.; Marlow M; Boehringer Ingelheim Pharmaceuticals Inc., Innovation Unit, Biotherapeutics Discovery, Ridgefield, CT, USA.
Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-6017 (Electronic) Linking ISSN: 00223549 NLM ISO Abbreviation: J Pharm Sci Subsets: MEDLINE
Academic Journal
Mostböck S; Cancer Immunology and Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Wu HH; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.; Fenn T; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.; Riegler B; Cancer Immunology and Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Strahlhofer S; Cancer Immunology and Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Huang Y; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.; Hansen G; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.; Kroe-Barrett R; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.; Tirapu I; Cancer Immunology and Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Vogt AB; Cancer Immunology and Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Academic Journal
Zippel N; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.; Kenny CH; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Wu H; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Garneau M; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.; Kroe-Barrett R; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Gupta P; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Low S; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Bakker RA; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.; Thomas L; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Publisher: Association for Research in Vision and Ophthalmology Country of Publication: United States NLM ID: 101595919 Publication Model: Print Cited Medium: Internet ISSN: 2164-2591 (Electronic) Linking ISSN: 21642591 NLM ISO Abbreviation: Transl Vis Sci Technol Subsets: MEDLINE
Academic Journal
Wurm M; Boehringer Ingelheim RCV, GmbH & Co KG, Cancer Pharmacology and Disease Positioning, Vienna, Austria.; Schaaf O; Boehringer Ingelheim RCV, GmbH & Co KG, Drug Discovery Sciences, Vienna, Austria.; Reutner K; Boehringer Ingelheim RCV, GmbH & Co KG, Cancer Immunology and Immune Modulation, Vienna, Austria.; Ganesan R; Boehringer Ingelheim Pharmaceuticals, Inc., Biotherapeutics Discovery, Ridgefield, Conneticut.; Mostböck S; Boehringer Ingelheim RCV, GmbH & Co KG, Cancer Immunology and Immune Modulation, Vienna, Austria.; Pelster C; Boehringer Ingelheim RCV, GmbH & Co KG, Cancer Immunology and Immune Modulation, Vienna, Austria.; Böttcher J; Boehringer Ingelheim RCV, GmbH & Co KG, Drug Discovery Sciences, Vienna, Austria.; de Andrade Pereira B; Boehringer Ingelheim Pharma GmbH, Cancer Immunology and Immune Modulation, Biberach, Germany.; Taubert C; Allcyte GmbH, Vienna, Austria.; Alt I; Allcyte GmbH, Vienna, Austria.; Serna G; Vall d´Hebron University Hospital, Vall d´Hebron Institute of Oncology, CIBERONC, Universitat Autonoma de Barcelona, Barcelona, Spain.; Auguste A; Boehringer Ingelheim Pharma GmbH & Co KG, Translational Medicine and Clinical Pharmacology, Biberach, Germany.; Stadermann KB; Boehringer Ingelheim Pharma GmbH & Co KG, Translational Medicine and Clinical Pharmacology, Biberach, Germany.; Delic D; Boehringer Ingelheim Pharma GmbH & Co KG, Translational Medicine and Clinical Pharmacology, Biberach, Germany.; Han F; Boehringer Ingelheim Pharmaceuticals, Inc., Biotherapeutics Discovery, Ridgefield, Conneticut.; Capdevila J; Vall d´Hebron University Hospital, Vall d´Hebron Institute of Oncology, CIBERONC, Universitat Autonoma de Barcelona, Barcelona, Spain.; Nuciforo PG; Vall d´Hebron University Hospital, Vall d´Hebron Institute of Oncology, CIBERONC, Universitat Autonoma de Barcelona, Barcelona, Spain.; Kroe-Barrett R; Boehringer Ingelheim Pharmaceuticals, Inc., Biotherapeutics Discovery, Ridgefield, Conneticut.; Adam PJ; Boehringer Ingelheim RCV, GmbH & Co KG, Cancer Immunology and Immune Modulation, Vienna, Austria.; Vogt AB; Boehringer Ingelheim RCV, GmbH & Co KG, Cancer Immunology and Immune Modulation, Vienna, Austria.; Hofmann I; Boehringer Ingelheim RCV, GmbH & Co KG, Cancer Immunology and Immune Modulation, Vienna, Austria. irmgard.hofmann@boehringer-ingelheim.com.
Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Academic Journal
Wu HH; Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA. Electronic address: helen.wu@boehringer-ingelheim.com.; Ralph KL; Boehringer Ingelheim Pharmaceuticals, Inc. Cancer Immunology & Immune Modulation, Ridgefield, CT, USA.; Sepuldeva E; Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA.; Hansen G; Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA.; Li H; Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA.; Huang ZF; Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA.; Liu D; Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA.; Dziegelewski M; Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA.; Ahlberg J; Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA.; Frego L; Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA.; Fogal S; Boehringer Ingelheim Pharmaceuticals, Inc. Immunology & Respiratory, Ridgefield, CT, USA.; van Tongeren S; Boehringer Ingelheim Pharmaceuticals, Inc. Nonclinical Drug Safety, Ridgefield, CT, USA.; Grimaldi C; Boehringer Ingelheim Pharmaceuticals, Inc. Drug Metabolism and Pharmacokinetics, Ridgefield, CT, USA.; Litzenberger T; Boehringer Ingelheim Pharmaceuticals, Inc. Translational Medicine & Clinical Pharmacology, Biberach, B-W, Germany.; Presky D; Presky Consulting. Scottsdale, AZ, USA.; Singh S; Janssen Biotherapeutics at Johnson & Johnson. Spring House, PA, USA.; Brodeur S; Janssen Pharmaceutical Companies at Johnson & Johnson. New Jersey, PA, USA.; Kroe-Barrett R; Boehringer Ingelheim Pharmaceuticals, Inc. Biotherapeutics Molecule Discovery, Ridgefield, CT, USA.
Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7804127 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3476 (Electronic) Linking ISSN: 03785173 NLM ISO Abbreviation: Int J Pharm Subsets: MEDLINE
Academic Journal
García-Martínez JM; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria. juan_manuel.garcia-martinez@boehringer-ingelheim.com.; Wang S; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria.; Weishaeupl C; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria.; Wernitznig A; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria.; Chetta P; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria.; Pinto C; Boehringer Ingelheim Cancer Immunology and Immune Modulation, Vienna, Austria.; Ho J; Boehringer Ingelheim Biotherapeutics Discovery Research, Ridgefield, Connecticut.; Dutcher D; Boehringer Ingelheim Biotherapeutics Discovery Research, Ridgefield, Connecticut.; Gorman PN; Boehringer Ingelheim Biotherapeutics Discovery Research, Ridgefield, Connecticut.; Kroe-Barrett R; Boehringer Ingelheim Biotherapeutics Discovery Research, Ridgefield, Connecticut.; Rinnenthal J; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria.; Giragossian C; Boehringer Ingelheim Biotherapeutics Discovery Research, Ridgefield, Connecticut.; Impagnatiello MA; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria.; Tirapu I; Boehringer Ingelheim Cancer Immunology and Immune Modulation, Vienna, Austria.; Hilberg F; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria.; Kraut N; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria.; Pearson M; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria.; Kuenkele KP; Boehringer Ingelheim Cancer Research Therapeutic Area, Vienna, Austria.
Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Academic Journal
Low S; Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Wu H; Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Jerath K; Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Tibolla A; Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Fogal B; Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Conrad R; Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; MacDougall M; Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Kerr S; Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Berger V; Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Dave R; Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Villalona J; Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Pantages L; Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Ahlberg J; Biotherapeutics Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Li H; Biotherapeutics Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Van Hoorick D; Project Management, Ablynx a Sanofi Company, Zwijnaarde, Belgium.; Ververken C; Project Management, Ablynx a Sanofi Company, Zwijnaarde, Belgium.; Broadwater J; Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Waterman A; Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Singh S; Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Kroe-Barrett R; Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.
Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101479829 Publication Model: Print Cited Medium: Internet ISSN: 1942-0870 (Electronic) Linking ISSN: 19420862 NLM ISO Abbreviation: MAbs Subsets: MEDLINE
검색 결과 제한하기
제한된 항목
[검색어] Kroe-Barrett, R.
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어